Literature DB >> 12199621

Myeloma aetiology and epidemiology.

G J Morgan1, F E Davies, M Linet.   

Abstract

Recently there have been substantial improvements in our understanding of the biology of myeloma. These findings have important implications for aetiological studies aimed at defining the causative factors for myeloma. Myeloma is closely related to monoclonal gammopathy of unknown significance (MGUS), which is now recognized to be very common in the older population. The epidemiology of these conditions is presented and discussed in the context of the genetic factors governing both the risk of developing MGUS or of transformation to myeloma. Biological studies support a role for aberrant class switch recombination early in the natural history of myeloma suggesting that factors in the environment may interact with this mechanism to increase myeloma risk. Case-control and cohort studies have identified several known and suspected environmental exposures. These exposures include high doses of ionizing radiation, and occupational exposure in the farming and petrochemical industries. The data supporting these associations are presented and discussed in the context of the molecular mechanisms underlying these exposures. In particular DNA damage occurring as a consequence could readily interact with the class switch recombination process to increase the risk of chromosomal translocations, oncogene deregulation and malignant transformation. A further hypothesis, which has been extensively investigated, is the role of chronic immune/antigenic stimulation and the risk of myeloma. This concept is difficult to explain in the context of our current immunological concepts. The data supporting the association and how molecular epidemiological studies using genetic variants in cytokine genes are allowing us to revisit this concept are discussed in detail.

Entities:  

Mesh:

Year:  2002        PMID: 12199621     DOI: 10.1016/s0753-3322(02)00194-4

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  12 in total

1.  Epidemiology of non-Hodgkin lymphomas in Tyrol/Austria from 1991 to 2000.

Authors:  T Mitterlechner; M Fiegl; H Mühlböck; W Oberaigner; S Dirnhofer; A Tzankov
Journal:  J Clin Pathol       Date:  2006-01       Impact factor: 3.411

Review 2.  Inherited genetic susceptibility to multiple myeloma.

Authors:  G J Morgan; D C Johnson; N Weinhold; H Goldschmidt; O Landgren; H T Lynch; K Hemminki; R S Houlston
Journal:  Leukemia       Date:  2013-11-19       Impact factor: 11.528

Review 3.  Equal Treatment and Outcomes for Everyone with Multiple Myeloma: Are We There Yet?

Authors:  Sikander Ailawadhi; Kirtipal Bhatia; Sonikpreet Aulakh; Zahara Meghji; Asher Chanan-Khan
Journal:  Curr Hematol Malig Rep       Date:  2017-08       Impact factor: 3.952

4.  Autologous stem cell transplantation in myeloma: the St James's Hospital experience, 1997-2003.

Authors:  P J Hayden; A O'Driscoll; N Gardiner; R Swords; J Sargent; F Ni Ainle; A Fortune; P T Murphy; M Leahy; F Jackson; M Ryan; B Hennessy; M Cahill; G M Crotty; H Enright; E Conneally; E Vandenberghe; S R McCann; P V Browne
Journal:  Ir J Med Sci       Date:  2005 Apr-Jun       Impact factor: 1.568

Review 5.  Cancer in Jews: introduction and overview.

Authors:  Henry T Lynch; Wendy S Rubinstein; Gershon Y Locker
Journal:  Fam Cancer       Date:  2004       Impact factor: 2.375

6.  Familial myeloma.

Authors:  Henry T Lynch; Kelly Ferrara; Bart Barlogie; Elizabeth A Coleman; Jane F Lynch; Dennis Weisenburger; Warren Sanger; Patrice Watson; Henry Nipper; Vinetta Witt; Stephan Thomé
Journal:  N Engl J Med       Date:  2008-07-10       Impact factor: 91.245

7.  Understanding the multiple biological aspects leading to myeloma.

Authors:  Eileen M Boyle; Faith E Davies; Xavier Leleu; Gareth J Morgan
Journal:  Haematologica       Date:  2014-04       Impact factor: 9.941

8.  Sequencing at lymphoid neoplasm susceptibility loci maps six myeloma risk genes.

Authors:  Rosalie Griffin Waller; Robert J Klein; Joseph Vijai; James D McKay; Alyssa Clay-Gilmour; Xiaomu Wei; Michael J Madsen; Douglas W Sborov; Karen Curtin; Susan L Slager; Kenneth Offit; Celine M Vachon; Steven M Lipkin; Charles Dumontet; Nicola J Camp
Journal:  Hum Mol Genet       Date:  2021-06-09       Impact factor: 6.150

9.  Multiple myeloma emerging after prolonged gefitinib treatment for non-small cell lung carcinoma.

Authors:  Sian Yik Lim; Sachiko Ando; Kaoru Nishiyama; Simi Padival
Journal:  Case Rep Oncol       Date:  2011-04-06

10.  Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma.

Authors:  Maroulio Pertesi; Maxime Vallée; Xiaomu Wei; Maria V Revuelta; Perrine Galia; Delphine Demangel; Javier Oliver; Matthieu Foll; Siwei Chen; Emeline Perrial; Laurent Garderet; Jill Corre; Xavier Leleu; Eileen M Boyle; Olivier Decaux; Philippe Rodon; Brigitte Kolb; Borhane Slama; Philippe Mineur; Eric Voog; Catherine Le Bris; Jean Fontan; Michel Maigre; Marie Beaumont; Isabelle Azais; Hagay Sobol; Marguerite Vignon; Bruno Royer; Aurore Perrot; Jean-Gabriel Fuzibet; Véronique Dorvaux; Bruno Anglaret; Pascale Cony-Makhoul; Christian Berthou; Florence Desquesnes; Brigitte Pegourie; Serge Leyvraz; Laurent Mosser; Nicole Frenkiel; Karine Augeul-Meunier; Isabelle Leduc; Cécile Leyronnas; Laurent Voillat; Philippe Casassus; Claire Mathiot; Nathalie Cheron; Etienne Paubelle; Philippe Moreau; Yves-Jean Bignon; Bertrand Joly; Pascal Bourquard; Denis Caillot; Hervé Naman; Sophie Rigaudeau; Gérald Marit; Margaret Macro; Isabelle Lambrecht; Manuel Cliquennois; Laure Vincent; Philippe Helias; Hervé Avet-Loiseau; Victor Moreno; Rui Manuel Reis; Judit Varkonyi; Marcin Kruszewski; Annette Juul Vangsted; Artur Jurczyszyn; Jan Maciej Zaucha; Juan Sainz; Malgorzata Krawczyk-Kulis; Marzena Wątek; Matteo Pelosini; Elzbieta Iskierka-Jażdżewska; Norbert Grząśko; Joaquin Martinez-Lopez; Andrés Jerez; Daniele Campa; Gabriele Buda; Fabienne Lesueur; Marek Dudziński; Ramón García-Sanz; Arnon Nagler; Marcin Rymko; Krzysztof Jamroziak; Aleksandra Butrym; Federico Canzian; Ofure Obazee; Björn Nilsson; Robert J Klein; Steven M Lipkin; James D McKay; Charles Dumontet
Journal:  Leukemia       Date:  2019-04-09       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.